Piper Sandler Has Lowered Expectations for Century Therapeutics (NASDAQ:IPSC) Stock Price
Century Therapeutics (NASDAQ:IPSC – Free Report) had its price objective cut by Piper Sandler from $4.00 to $2.00 in a report issued on Thursday,Benzinga reports. They currently have an overweight rating on the stock. Several other brokerages have also recently commented on IPSC. HC Wainwright reissued a “buy” rating and issued a $5.00 price target […]
Century Therapeutics (NASDAQ:IPSC – Free Report) had its price objective cut by Piper Sandler from $4.00 to $2.00 in a report issued on Thursday,Benzinga reports. They currently have an overweight rating on the stock. Several other brokerages have also recently commented on IPSC. HC Wainwright reissued a “buy” rating and issued a $5.00 price target […]
